Sep 11, 2023 / 11:00AM GMT
Steve Bersey - H.C. Wainwright & Co., LLC - Analyst
Good day, everyone, and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Steve Bersey. I'm an equity research associate here at H.C. Wainwright.
So now, I'd like to welcome Tempest Therapeutics.
Sam Whiting - Tempest Therapeutics, Inc. - Chief Medical Officer and Head of R&D
Sam Whiting, Chief Medical Officer at Tempest. Tempest would like to thank H.C. Wainwright for the opportunity to present at the 25th Annual Investment Conference. Tempest is a publicly traded company, and I will be making forward-looking statements. Please see our most recent SEC filings.
Tempest Therapeutics is a small but experienced biotech company that exemplifies a diversified opportunity in the oncology space. We have multiple programs, spanning from randomized Phase 2 data in a globally relevant indication in the first-line setting down to novel preclinical programs that are still undisclosed in order to maintain our development advantage.
Our
Tempest Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers